Mielóma multiplex: vizsgálatok itt: Kanada
42 of 47 trials · From ClinicalTrials.gov, checked 2026. november 18.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Where
- Montreal, Winnipeg
- Életkor
- 18 év and over
- People
- 183 worldwide
- Run by
- Takeda
See details and how to joinNCT06980480 · EU 2024-518420-80-00 - 3. fázisTaking peopleMagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Where
- Moncton, Montreal
- Életkor
- 18 év and over
- People
- 492 worldwide
- Run by
- Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00 - 4. fázisTaking peopleImmunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
- Where
- Lévis, Montreal, Québec
- Életkor
- 18 év and over
- People
- 80
- Run by
- CHU de Quebec-Universite Laval
See details and how to joinNCT07094048 - 1. fázisTaking peopleA Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Hamilton, Ottawa
- Életkor
- 18 év and over
- People
- 250 worldwide
- Run by
- AbbVie
See details and how to joinNCT05650632 · EU 2023-504674-38-00 - 3. fázisTaking peopleCevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
- Where
- Hamilton
- Életkor
- 18 év and over
- People
- 380 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07555938 · EU 2025-524028-23-00 - 3. fázisFut, nem toborozA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Calgary, Edmonton, Oshawa, Québec, Vancouver
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Calgary, Halifax, Hamilton, London, Montreal, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00 - 3. fázisFut, nem toborozA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Greenfield Park, Montreal, Québec
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 1/2. fázisTaking peopleAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Where
- Hamilton, Montreal, Nova Scotia, Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Calgary, Halifax, Hamilton, Montreal, Vancouver
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Calgary, Edmonton, Fredericton, Halifax, Sherbrooke, Toronto
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peopleA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Where
- Edmonton, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 246 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00 - No phaseTaking peoplePrehab Prior to Stem Cell Transplantation in Multiple Myeloma
- Where
- Edmonton
- Életkor
- 18 év and over
- People
- 30
- Run by
- University of Alberta
See details and how to joinNCT06280924 - 1. fázisTaking peopleA Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Where
- Edmonton, Toronto
- Életkor
- 18 év and over
- People
- 165 worldwide
- Run by
- K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00 - 3. fázisNot yet taking people in KanadaA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Calgary, Halifax, Montreal, Sherbrooke
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637 - 1. fázisFut, nem toborozA Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Edmonton, Hamilton, Toronto
- Életkor
- 18 év and over
- People
- 186 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT04910568 · EU 2023-507019-36-00 - 3. fázisTaking peopleFixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
- Where
- Barrie, Brampton, Edmonton, Hamilton, Kelowna, Kingston, Kitchener, London, Mississauga, Moncton, Montreal, Newmarket, Oakville, Oshawa, Ottawa, Québec, Regina, Saint John, Saskatoon, Sault Ste. Marie, St. Catharines, St. John's, Thunder Bay, Toronto, Vancouver, Windsor, Winnipeg
- Életkor
- 18 év and over
- People
- 570
- Run by
- Canadian Cancer Trials Group
See details and how to joinNCT06182774 - 3. fázisNot yet taking people in KanadaSingle-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Where
- Fredericton, Montreal
- Életkor
- 18 év and over
- People
- 63 worldwide
- Run by
- CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00 - 2. fázisTaking peopleStudy of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Calgary, Montreal
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06297226 - No phaseTaking peoplePET/MR Scan With [68Ga]Ga-PentixaFor (CXCR4) vs Standard of Care (SOC) for Initial Staging and Follow up in Multiple Myeloma (MM)
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 30
- Run by
- University Health Network, Toronto
See details and how to joinNCT06871176 - 3. fázisTaking peopleA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
- Where
- Calgary, Montreal, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 508 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07391657 - 2. fázisTaking peopleOutpatient and Intermittent Dosing of Elranatamab in Relapsed/Refractory Multiple Myeloma
- Where
- Hamilton, Kingston, London, Ottawa, Vancouver, Victoria
- Életkor
- 18 év and over
- People
- 40
- Run by
- Ontario Clinical Oncology Group (OCOG)
See details and how to joinNCT06421675 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Calgary, Edmonton, Oshawa, Toronto
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07518186 - 1. fázisNot yet taking people in KanadaStudy of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE)
- Where
- Edmonton, Halifax, London, Montreal, Ottawa, Toronto
- Életkor
- 18 év to 100 év
- People
- 108
- Run by
- Canadian Myeloma Research Group
See details and how to joinNCT07831122